Please login to the form below
Breo
This page shows the latest Breo news and features for those working in and with pharma, biotech and healthcare.
Advair generics and acquisitions to hit GSK in 2019
However the tough US market took a bite out of Breo Ellipta, which saw sales decline (3% AER, 1% CER) because of pricing pressure, despite strong volume growth.
Latest news
-
GSK gets maintenance indication for Trelegy
GSK claims Trelegy has made the strongest start of any of GSK’s new Ellipta range of respiratory meds, which also includes Relvar/Breo (fluticasone furoate/vilanterol) and Anoro (vilanterol/umeclidinium
-
EMA approves GSK’s triple COPD therapy
GSK has been bringing other new COPD therapies to market - including Advair successor Breo/Relvar (fluticasone furoate and vilanterol) and Anoro (umeclidinium bromide and vilanterol) - but with greater competition in the
-
With US approval, GSK now needs rapid uptake for COPD triple
Specifically, Trelegy has been approved as an upgraded treatment for patients on GSK's Breo (fluticasone furoate/vilanterol) and still need to improve airflow or reduce exacerbations, and as an alternative ... for those on triple therapy with Breo and
-
GSK closes in on EU approval for triple COPD therapy
product, now facing sales declines because of generic competition, and follow-up Breo (vilanterol/fluticasone furoate).
-
GSK's Witty ends on a high, but warns 2017 looking 'uncertain'
At the moment, new respiratory products such as Relvar/Breo (fluticasone furoate/vilanterol) are covering the decline in Advair, which fell 20% to £975m ($1.2bn) in the fourth quarter of ... Overall, group sales rose 21% year-on-year to £7.6bn, around
More from news
Approximately 11 fully matching, plus 30 partially matching documents found.
Latest Intelligence
-
Pharma deals during May 2013
First in this was the purchase for $1bn of 21 per cent of the respiratory product royalties Theravance receives, including the royalties on the recently US approved Breo for COPD being
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Breo and Anoro late stage development programmes.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Gilead announces positive Biktarvy data for HIV and hepatitis B
- Janssen announces positive results supporting Rybrevant and lazertinib combination treatment for NSCLC
- Medscape Education Receives Joint Accreditation with Commendation to Deliver Continuing Education for Healthcare Providers
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
- NHS England to roll out continuous glucose monitors to all those with type 1 diabetes
- Sanofi and Innovent Biologics to develop oncology drugs for patients in China
- WHO launches funding appeal for greater Horn of Africa prompted by food crisis
PMHub
Origins Insights
Origins are part of the Resonant Group. Using novel research methodologies, we dig deeper to deliver authentic audience experiences that...
Latest intelligence
- Animation: Living With
- The journey from the patient's perspective...
- Achieving communication excellence by targeting the right channel at the right time
- By Danny Buckland...
- 6 trends shaping the future of personalized medicine
- Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
